Dark

XENE
Xenon Pharmaceuticals Inc
stock NASDAQ

At Close

Sep 17, 2026 3:59:55 PM EDT

57.36USD+1.057%(+0.60)1,479,762

0.00Bid 0.00Ask 0.00Spread

Pre-market

Sep 14, 2026 8:40:30 AM EDT

58.40USD+2.889%(+1.64)0

After-hours

Sep 17, 2026 4:59:30 PM EDT

43.75USD-23.727%(-13.61)289,306

OverviewOptionsHistoricalExchangesShortsNews

Jan 12, 2022

08:06AM EST Xenon Pharma Reports Collab With Neurocrine Biosciences To Develop Treatments For Epilepsy Reached Regulatory Milestone, Triggering $15M Payment To Xenon Benzinga

08:00AM EST Xenon Pharmaceuticals Announces Collaboration with Neurocrine GlobeNewswire Inc

Jan 10, 2022

08:30AM EST Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today outlined its key milestones for 2022. GlobeNewswire Inc

Dec 3, 2021

07:40AM EST The Daily Biotech Pulse: Protagonist Pulls Plug On Phase 1 Asset, Xenon Aces Mid-Stage Epilepsy Study, Esperion Prices Offering Benzinga

07:03AM EST Xenone Pharma Highlights Presentation Of Added Positive Data From Phase 2b 'X-TOLE' Trial At Annual Meeting Of American Epilepsy Society: Data Showed All Primary, Secondary Endpoint Reductions Were Statistically Significant Benzinga

07:00AM EST Topline Data Showed All Primary and Secondary Seizure Reduction Endpoints Statistically Significant Across All Dose Groups, with p-value of <0.001 for 20 mg and 25 mg Dose Groups GlobeNewswire Inc

06:56AM EST Xenon Pharma Offers Update On Its Neurology Programs At Annual Meeting Of American Epilepsy Society Benzinga

06:55AM EST Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that it will provide updates on its proprietary, neurology programs at the Annual Meeting of the American Epilepsy Society (AES 2021). GlobeNewswire Inc

Nov 28, 2021

09:43AM EST The Week Ahead In Biotech (Nov. 28-Dec. 4): FDA Decisions For VBI Vaccines, BeyondSpring, CTI Biopharma And Merck Take The Spotlight In A Light Calendar Week Benzinga

Nov 12, 2021

08:30AM EST Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that Ian Mortimer, Xenons President and Chief Executive Officer, along with Sherry Aulin, Xenons Chief Financial Officer, will participate virtually in the following investor conferences: GlobeNewswire Inc

Nov 11, 2021

04:59AM EST SVB Leerink Maintains Outperform on Xenon Pharmaceuticals, Raises Price Target to $40 Benzinga

Nov 10, 2021

04:39PM EST Xenon Pharmaceuticals Q3 EPS $(0.36) Beats $(0.38) Estimate, Sales $8.12M Miss $10.22M Estimate Benzinga

04:01PM EST XEN1101 X-TOLE Presentations Scheduled at AES 2021 with Planning Underway for Phase 3 Initiation in 2022 GlobeNewswire Inc

04:09AM EST Earnings Scheduled For November 10, 2021 Benzinga

Nov 3, 2021

04:01PM EDT Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its third quarter 2021 financial and operating results after the close of U.S. financial markets on Wednesday, November 10, 2021. GlobeNewswire Inc

Oct 28, 2021

10:48AM EDT Benzinga's Top Ratings Upgrades, Downgrades For October 28, 2021 Benzinga

07:13AM EDT RBC Capital Initiates Coverage On Xenon Pharmaceuticals with Outperform Rating, Announces Price Target of $43 Benzinga

Oct 14, 2021

12:13PM EDT Shares of Xenon Pharmaceuticals Inc. Have Risen Above Previous 52-Week High Benzinga

Oct 10, 2021

11:59AM EDT The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations and IPOs Take Center Stage Benzinga

Oct 8, 2021

02:15PM EDT Xenon Pharmaceuticals Announces Closing of $345 Million Public GlobeNewswire Inc

Oct 6, 2021

07:33AM EDT The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal Benzinga

Oct 5, 2021

10:36PM EDT Xenon Pharmac Announces Pricing Of $300.0 Mln Public Offering RTTNews

09:54PM EDT Xenon Pharmaceuticals Announces Pricing of $300.0 Million Public GlobeNewswire Inc

08:01AM EDT The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout Benzinga

Oct 4, 2021

04:09PM EDT Xenon Pharma Reports Commenced $250M Common Stock Shelf Offering Benzinga

04:08PM EDT Xenon Pharmaceuticals Announces Proposed Public Offering GlobeNewswire Inc

04:04PM EDT Xenon Pharma Filing Shows Registration For Mixed Securities Shelf Offering, No Size Disclosed Benzinga

02:32PM EDT Mid-Afternoon Market Update: Dow Drops 375 Points; Elmira Savings Bank Shares Spike Higher Benzinga

12:47PM EDT Needham Maintains Buy on Xenon Pharmaceuticals, Raises Price Target to $48 Benzinga

12:17PM EDT Mid-Day Market Update: Nasdaq Down 2%; Xenon Pharmaceuticals Shares Jump Benzinga

11:23AM EDT Hearing Jefferies Raises Price Target On Xenon Pharma From $28 To $50 Benzinga

10:15AM EDT Mid-Morning Market Update: Markets Mostly Lower; US Factory Orders Surpass Estimates Benzinga

10:09AM EDT UPDATE: William Blair Calls Xenon Pharma's XEN1101 Data 'incredibly strong and represent a best-case scenario from the study from an efficacy perspective...' Benzinga

10:08AM EDT Xenon Pharmaceuticals Shares Up 76%; William Blair Raises Price Target From $30 To $46; Raises Probability Of Success For XEN1101 In FOS From 60% To 85% Benzinga

10:07AM EDT Why Xenon Pharmaceuticals Stock Is Soaring Today Benzinga

10:05AM EDT Xenon Pharmaceuticals Shares Up 76%; William Blair Raises Price Target From $30 To $46; Hearing Raises Probability Of Success For XEN1101 In FOS From 60% To 85% Benzinga

09:49AM EDT Xenon Pharmaceuticals Shares Up 76%; Hearing William Blair Raises Price Target From $30 To $46; Hearing Raises Probability Of Success For XEN1101 In FOS From 60% To 85% Benzinga

07:25AM EDT Xenon Pharma Reportss Positive Topline Results From Phase 2b 'X-TOLE' Clinical Trial Of XEN1101 For Focal Epilepsy RTTNews

07:09AM EDT Xenon Pharmaceuticals Announces Topline Results From Phase 2b 'X-TOLE' Clinical Trial of XEN1101 For The Treatment Of Focal Epilepsy; Co. Reports 'All Primary and Secondary Seizure Reduction Endpoints Statistically Significant Across All Dose Groups' Benzinga

07:00AM EDT All Primary and Secondary Seizure Reduction Endpoints Statistically Significant Across All Dose Groups, with p-value of <0.001 for 20 mg and 25 mg Dose Groups GlobeNewswire Inc

06:58AM EDT Xenon Pharmaceuticals On Sunday Announced The Co. Will Have A Conference Call And Webcast To Discuss Topline Results From Phase 2b 'X-TOLE' Clinical Trial Of XEN1101 Benzinga

Oct 3, 2021

04:32PM EDT Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that Xenon management will host a conference call and webcast to discuss topline results from the XEN1101 Phase 2b X-TOLE clinical trial on Monday, October 4, 2021 at 7:30 am Eastern Time. GlobeNewswire Inc

Sep 28, 2021

12:15PM EDT Xenon Pharmaceuticals Earnings Perspective: Return On Capital Employed Benzinga

Sep 8, 2021

08:35AM EDT Xenon Pharmaceuticals Announces Epilepsy Collaboration With Neurocrine Biosciences AChieved Regulatory Milestone, Triggering $10M Payment To Co. Benzinga

08:30AM EDT Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that its collaboration to develop treatments for epilepsy with Neurocrine Biosciences, Inc. (Nasdaq: NBIX) achieved a regulatory milestone with the approval of a clinical trial application (CTA) in Europe, triggering an aggregate payment of $10.0 million to Xenon. GlobeNewswire Inc

Aug 23, 2021

08:34AM EDT Xenon Pharma Appoints Christopher Kenney As Chief Medical Officer RTTNews

08:30AM EDT Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced the appointment of Christopher Kenney, M.D. as Chief Medical Officer, effective immediately. Dr. Kenney will oversee all clinical development and medical affairs strategies, guiding the development of Xenons portfolio of neurology-focused therapeutic programs. GlobeNewswire Inc

Aug 11, 2021

04:16PM EDT Xenon Pharmaceuticals Q2 EPS $(0.51) Misses $(0.48) Estimate, Sales $2.22M Miss $2.33M Estimate Benzinga

04:01PM EDT Topline Data from XEN1101 Phase 2b X-TOLE Clinical Trial Anticipated Late September to Mid-October 2021 GlobeNewswire Inc

09:06AM EDT Earnings Scheduled For August 11, 2021 Benzinga

08:14AM EDT The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering Benzinga

04:27AM EDT Earnings Scheduled For August 11, 2021 Benzinga

Aug 9, 2021

11:07AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

Aug 4, 2021

04:01PM EDT Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its second quarter 2021 financial and operating results after the close of U.S. financial markets on Wednesday, August 11, 2021. GlobeNewswire Inc

Jul 7, 2021

08:37AM EDT Xenon Pharmaceuticals Announces Completion Of Patient Randomization In XEN1101 Phase 2b 'X-TOLE' Clinical Trial, Announces Upcoming Investor Webinar Benzinga

08:30AM EDT Xenon Pharmaceuticals Announces Completion of Patient GlobeNewswire Inc

Jun 18, 2021

10:21AM EDT Return On Capital Employed Overview: Xenon Pharmaceuticals Benzinga

Jun 4, 2021

10:49AM EDT Looking Into Xenon Pharmaceuticals's Return On Capital Employed Benzinga

Jun 3, 2021

05:45PM EDT Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, provided a corporate update following its 2021 Annual Meeting of Shareholders (the Annual Meeting) held today on June 3, 2021. GlobeNewswire Inc

10:28AM EDT Xenon Pharma ClinicalTrials.gov Study Record Detail For Co.'s 'An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE (EPIK-OLE),' Shows Not Yet Recruiting Benzinga

May 31, 2021

04:01PM EDT Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that members of its executive management team will participate in the following investor conference: GlobeNewswire Inc

May 11, 2021

04:15PM EDT Xenon Pharmaceuticals Q1 EPS $(0.42) Misses $(0.40) Estimate, Sales $4.36M Miss $5.15M Estimate Benzinga

04:01PM EDT Topline Data from XEN1101 Phase 2b X-TOLE Clinical Trial Anticipated by End of Third Quarter of 2021 GlobeNewswire Inc

12:47PM EDT Earnings Scheduled For May 11, 2021 Benzinga

May 10, 2021

10:08AM EDT Xenon Pharmaceuticals's Earnings Outlook Benzinga

May 4, 2021

04:05PM EDT Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced it will report its first quarter 2021 financial and operating results after the close of U.S. financial markets on Tuesday, May 11, 2021. GlobeNewswire Inc

Apr 8, 2021

04:03PM EDT Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that members of its executive management team will present a corporate overview and participate in the following virtual investor conferences: GlobeNewswire Inc

Mar 29, 2021

04:05PM EDT Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that the Company will participate in a fireside chat at the following virtual investor conference: GlobeNewswire Inc

Mar 12, 2021

12:19PM EST Xenon Pharmaceuticals Announces Closing of $115 Million Public GlobeNewswire Inc

Mar 10, 2021

07:26AM EST The Daily Biotech Pulse: MediciNova Bags BARDA Contract, Lilly's COVID-19 Antibody Cocktail Data, Bluebird Bio Refutes Blood Cancer Link Benzinga

12:50AM EST Xenon Pharmaceuticals Announces Pricing of $100.0 Million Public GlobeNewswire Inc

Mar 9, 2021

04:06PM EST Xenon Pharmaceuticals Announces A Common Stock Offering; No Price Disclosed Benzinga

04:05PM EST Xenon Pharmaceuticals Announces Proposed Public Offering of Common GlobeNewswire Inc

09:17AM EST The Daily Biotech Pulse: Regulatory Setback For Acadia, Lilly Forges Diabetes Antibody Treatment Collaboration, Aytu's Positive COVID-19 Data Benzinga

Mar 8, 2021

04:06PM EST Xenon Pharmaceuticals Announces Collaboration with Researchers at Icahn School of Medicine at Mount Sinai to Conduct a Phase 2 Study of XEN1101 for the Treatment of Major Depressive Disorder Benzinga

04:05PM EST Xenon Pharmaceuticals Announces Collaboration with Researchers at GlobeNewswire Inc

Mar 3, 2021

07:46AM EST The Daily Biotech Pulse: KemPharm ADHD Drug Gets The Nod, MediciNova Shelves Vaccine Study Benzinga

Mar 2, 2021

08:01AM EST The Daily Biotech Pulse: Roxadustat Delay For FibroGen, AstraZeneca, Decision Day For KemPharm, NanoViricides Jumps On COVID-19 Drug Data Benzinga

07:00AM EST Needham Maintains Buy on Xenon Pharmaceuticals, Raises Price Target to $25 Benzinga

05:09AM EST SVB Leerink Maintains Outperform on Xenon Pharmaceuticals, Raises Price Target to $28 Benzinga

Mar 1, 2021

05:25PM EST Recap: Xenon Pharmaceuticals Q4 Earnings Benzinga

04:06PM EST Xenon Pharmaceuticals Reports FY20 EPS $(0.81) Up From $(1.54) YoY, Sales $32.166M Up From $6.829M YoY Benzinga

04:01PM EST XEN1101 Phase 2b X-TOLE Clinical Trial in Adult Focal Epilepsy on Track for Topline Data inThird Quarter of 2021 GlobeNewswire Inc

03:51AM EST Earnings Scheduled For March 1, 2021 Benzinga

Feb 27, 2021

09:04PM EST The Week Ahead In Biotech (Feb. 28-March 6): KemPharm, Gilead FDA Decisions and More Earnings Benzinga

Feb 25, 2021

08:08AM EST The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants Benzinga

Feb 23, 2021

08:45AM EST Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced it will report its 2020 financial and operating results after the close of U.S. financial markets on Monday, March 1, 2021: GlobeNewswire Inc

Feb 22, 2021

04:03PM EST Xenon Pharmaceuticals To Present XEN1101 Sata At ASENT 2021 Benzinga

04:01PM EST Pre-Clinical Data Support the Potential Benefit of XEN1101 to Treat Depression and Anhedonia GlobeNewswire Inc

Jan 14, 2021

08:10AM EST Xenon Anticipate Number Of Key Milestone Events Looking Ahead To 2021 RTTNews

08:02AM EST Xenon Pharmaceuticals Outlines Milestone Opportunities And Announces Ian Mortimer To Be Named Chief Executive Officer At Annual Meeting of Shareholders in June 2021 Benzinga

08:00AM EST Simon Pimstone to Assume New Role as Executive Chair and Ian Mortimer to be Named Chief Executive Officer at Annual Meeting of Shareholders in June 2021 GlobeNewswire Inc

Dec 7, 2020

04:03PM EST Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, announced updates on its proprietary and partnered neurology programs at AES2020, the virtual Annual Meeting of the American Epilepsy Society. GlobeNewswire Inc

Dec 4, 2020

08:04AM EST The Daily Biotech Pulse: BioCryst's Heredity Angioedema Treatment Clears FDA, Sutro Biopharma Readout, 2 IPOs Benzinga

Nov 29, 2020

08:59AM EST The Week Ahead In Biotech: Hematology Conference Gets Underway, Vanda And BioCryst Await FDA Decisions Benzinga

Nov 13, 2020

09:00AM EST Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's Chief Executive Officer, will participate in the following virtual investor conferences: GlobeNewswire Inc

Nov 5, 2020

04:03PM EST Xenon Pharmaceuticals Q3 EPS $(0.25) Misses $(0.15) Estimate, Sales $6.55M Miss $10.06M Estimate Benzinga

04:34AM EST Earnings Scheduled For November 5, 2020 Benzinga

Nov 2, 2020

05:26PM EST Xenon Pharmaceuticals to Host Conference Call and Webcast to GlobeNewswire Inc

Oct 8, 2020

10:02AM EDT Neurocrine Biosciences, Xenon Pharmaceuticals Provide Regulatory Update On Ongoing Collaboration To Develop First-In-Class Treatment For Epilepsy; Says FDA Grants Rare Pediatric Disease Designation For NBI-921352 For Treatment Of SCN8A-DEE Benzinga

08:21AM EDT Neurocrine Biosciences And Xenon Pharmaceuticals Report FDA Is Requesting Additional Non-clinical Data To Support Dose Justification In Pediatric Study Of NBI-921352 Benzinga

08:07AM EDT Xenon Pharma Gets FDA Feedback And Is On Track To Initiate XEN496 Phase 3 Clinical Trial Before Year-End RTTNews

08:06AM EDT Xenon Pharmaceuticals Receives FDA Feedback And Says Is On Track To Initiate XEN496 Phase 3 Clinical Trial For Treatment Of KCNQ2-DEE Before Year-End Benzinga

08:02AM EDT Xenon Pharmaceuticals Receives FDA Feedback and is on Track to GlobeNewswire Inc

08:00AM EDT U.S. Food and Drug Administration(FDA) Requests Additional Non-Clinical Data to Support Dose Justification Before Initiation of a Phase II Clinical Trial with NBI-921352 in Pediatric SCN8A-DEE Patients GlobeNewswire Inc

Oct 2, 2020

10:39AM EDT Benzinga's Top Upgrades, Downgrades For October 2, 2020 Benzinga

06:15AM EDT SVB Leerink Initiates Coverage On Xenon Pharmaceuticals with Outperform Rating, Announces Price Target of $22 Benzinga

Aug 17, 2020

08:40AM EDT Xenon Appoints Chris Von Seggern As Chief Commercial Officer RTTNews

08:30AM EDT Xenon Pharmaceuticals Appoints Dr. Chris Von Seggern as Chief GlobeNewswire Inc

Aug 6, 2020

04:13PM EDT Xenon Pharmaceuticals Q2 Sales $13.38M Beat $6.90M Estimate Benzinga

Aug 4, 2020

04:01PM EDT Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's Chief Executive Officer, will participate in the following virtual investor conferences: GlobeNewswire Inc

Jul 21, 2020

09:58AM EDT CORRECTION: Needham Initiation Of Xenon Pharmaceuticals Stock Was Issued On Monday; Headline Indicating Initiation Of Coverage Tuesday Was A Repeat Benzinga

05:22AM EDT Needham Initiates Coverage On Xenon Pharmaceuticals with Buy Rating, Announces Price Target of $22 Benzinga

Jul 20, 2020

04:22PM EDT Needham Initiates Coverage On Xenon Pharmaceuticals With Buy Rating And $22 Price Target Benzinga